Dr. Carr is the Branch Chief of the Clinical Research Branch in the Division of Tuberculosis Elimination at the U.S. Centers for Diseases Control (CDC).  She has more than 15 years of experience in clinical research, most recently several Phase II and III trials conducted by the Tuberculosis Trials Consortium (TBTC) for treatment of active TB as well as latent TB Infection.  Her previous work in infectious disease and vaccine research studies include the phase II/III STRIVE trial (Sierra Leone Trial to Introduce a Vaccine against Ebola) at CDC and earlier phase I and preclinical studies at the NIH Division of Microbiology and Infectious Diseases. She recently led the development of CDC Guidance for the 4-month rifapentine-moxifloxacin regimen for treatment of active TB that was published less than a year following the successful results of TBTC Study 31/ACTG 5349.